Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
Florence O BadaNick BlokEvaezi OkpokoroSaswata DuttChristopher AkoloPatrick DakumAlash'le AbimikuPublished in: PloS one (2020)
Replacing Models A-C with Models D and E reduced the costs of RR/MDR-TB care in Nigeria by approximately $5,470 (48%) per patient treated and transitioning from Models D and E to Model F would result in further cost savings of $914 to $4,285 (21 to 56%) for every patient placed on Model F. If the improved outcomes of patients managed using bedaquiline-containing shorter treatment regimens in other countries can be attained in Nigeria, Model F would be the recommended model for the scale up of RR/MDR-TB care in Nigeria.
Keyphrases
- drug resistant
- multidrug resistant
- mycobacterium tuberculosis
- healthcare
- palliative care
- acinetobacter baumannii
- newly diagnosed
- case report
- pain management
- combination therapy
- type diabetes
- pulmonary tuberculosis
- skeletal muscle
- chronic pain
- cystic fibrosis
- insulin resistance
- hiv aids
- affordable care act
- adverse drug
- patient reported
- antiretroviral therapy
- smoking cessation